Indication · GI, Urology & Nephrology
Prostate cancer
Last checked: Nov 20, 2026Source: FDA, ClinicalTrials.gov
Devices
112
Cleared or approved since 2000
PMA and De Novo
71
Higher-risk or first-of-kind devices
Breakthrough devices
4
Authorized through June 30, 2026
Recruiting device trials
92
533 device trials in all
Breakthrough-designated devices
- IsoPSA AssayCleveland Diagnostics, Inc. · 2025
3 more devices with a free account
Devices
41 devices via 510(k). PMA and De Novo devices first, then devices with the most FDA decisions. Each opens a full summary.
- TULSA-PRO System
Profound Medical, Inc. · 510(k) · High Intensity Ultrasound System For Prostate Tissue Ablation · newest 2023 · 4 decisions
40 more devices with a free account
Device trials
Device studies on ClinicalTrials.gov for this condition, any status, newest update first.
Washington University School of MedicineAcademic, hospital or other
NCT07723651 · 75 participants (planned) · Start Nov 30, 2026 · Primary completion May 31, 2032
Device: FTT-PET/CT · For: Metastatic Prostate Cancer; Prostate Cancer
Sites: St Louis, Missouri; Philadelphia, Pennsylvania; Houston, Texas
532 more trials with a free account
Device types
FDA product codes mapped to this indication. The mapping was made with AI help and may include a few loose fits.
- Prostate-Specific Antigen (Psa) For Management Of Prostate Cancers (LTJ)31
- Total, Prostate Specific Antigen (Noncomplexed & Complexed) For Detection Of Prostate Cancer (MTF)20
- Test, Prostate Specific Antigen, Free, (Noncomplexed) To Distinguish Prostate Cancer From Benign Conditions (MTG)16
- Antigen(Complexed),Prostate Specific,(Cpsa) (NAF)10
- High Intensity Ultrasound System For Prostate Tissue Ablation (PLP)8
- Hydrogel Spacer (OVB)7
- Prostate Immobilizer Rectal Balloon (PCT)5
- Probe And Director, Gastro-Urology (FGM)4
- Software Algorithm Device To Assist Users In Digital Pathology (QPN)2
- Multi-Analyte Test System With Algorithmic Analysis For Detection Of Prostate Cancer (QRF)2
- Seed, Isotope, Gold, Titanium, Platinum (IWG)1
- Acid Phosphatase (Prostatic), Tartrate Inhibited (JFH)1
- Immunohistochemical Reagent, Antibody (Monoclonal Or Polyclonal) To P63 Protein In Nucleus Of Prostatic Basal Cells (NTR)1
- Prostate Lesion, Documentation, System (OQT)1
- Prostate-Specific Antigen (Psa) For Prognostic, Recurrence Risk Assessment Of Prostate Cancers (OWM)1
- P2psa (OYA)1
- Pathology Software Algorithm Device Analyzing Digital Images For Prostate Cancer Prognosis (SFH)1
Research
- Device studies on prostate cancer across PubMed, Europe PMC and OpenAlex
- PubMed ↗
- Google Scholar ↗
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.